PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer

18:26 EDT 1 Jun 2019 | ecancermedicalscience

Dr Sara A. Hurvitz talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of PARP inhibitors in patients with metastatic BRCA1 and BRCA2 breast cancer and how they offer a promising alternative to...

More From BioPortfolio on "PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer"